According to Morgan Keegan, Boston Scientific BSX had a good quarter.
Morgan Keegan said that the quarter was good coming in at the high end or beating consensus, but the story still is that the company is meeting its long-term strategic plan's milestones. “Third quarter estimates lowered because of CRM weakness as well has higher SG&A and tax expenses; however yearly EPS guidance raised to $0.64-$0.70 ($0.41-$0.47 inc. amort.) from $0.58-$0.68 ex. amortization.”
Boston Scientific closed yesterday at $7.28.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in